Masimo Co. (MASI) Given Consensus Recommendation of “Buy” by Analysts

Shares of Masimo Co. (NASDAQ:MASI) have been given a consensus recommendation of “Buy” by the eight ratings firms that are presently covering the company, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $139.13.

MASI has been the topic of several recent research reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $139.00 price target on shares of Masimo in a report on Friday, February 1st. Zacks Investment Research downgraded shares of Masimo from a “hold” rating to a “sell” rating in a report on Thursday, January 3rd. BidaskClub raised shares of Masimo from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 31st. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $140.00 price target on shares of Masimo in a report on Wednesday, February 27th. Finally, BTIG Research downgraded shares of Masimo from a “buy” rating to a “neutral” rating and set a $134.50 price target on the stock. in a report on Tuesday, April 16th.

In related news, Director Steven Barker sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, March 28th. The shares were sold at an average price of $135.00, for a total transaction of $1,350,000.00. Following the completion of the transaction, the director now owns 74,832 shares of the company’s stock, valued at $10,102,320. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jon Coleman sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, February 25th. The stock was sold at an average price of $130.00, for a total transaction of $260,000.00. Following the transaction, the insider now directly owns 13,201 shares of the company’s stock, valued at approximately $1,716,130. The disclosure for this sale can be found here. In the last three months, insiders sold 35,722 shares of company stock valued at $4,832,310. Company insiders own 11.50% of the company’s stock.

A number of hedge funds have recently modified their holdings of MASI. West Oak Capital LLC acquired a new stake in shares of Masimo in the first quarter worth $28,000. Claybrook Capital LLC acquired a new stake in shares of Masimo in the fourth quarter worth $25,000. Ruggie Capital Group acquired a new stake in shares of Masimo in the fourth quarter worth $33,000. Financial Gravity Companies Inc. acquired a new stake in shares of Masimo in the fourth quarter worth $49,000. Finally, Quantamental Technologies LLC acquired a new stake in shares of Masimo in the fourth quarter worth $43,000. 83.88% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ MASI traded up $3.53 on Thursday, hitting $127.11. The company’s stock had a trading volume of 36,955 shares, compared to its average volume of 437,543. Masimo has a 12-month low of $88.09 and a 12-month high of $141.05. The company has a market capitalization of $6.59 billion, a PE ratio of 41.94, a price-to-earnings-growth ratio of 2.55 and a beta of 1.19.

Masimo (NASDAQ:MASI) last announced its quarterly earnings results on Tuesday, February 26th. The medical equipment provider reported $0.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.11. Masimo had a net margin of 22.55% and a return on equity of 19.53%. The company had revenue of $223.10 million for the quarter, compared to the consensus estimate of $220.96 million. During the same quarter in the prior year, the firm earned $0.72 earnings per share. The company’s revenue for the quarter was up 7.3% compared to the same quarter last year. As a group, equities research analysts expect that Masimo will post 3.08 earnings per share for the current fiscal year.

Masimo Company Profile

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

Further Reading: Do stock splits help investors?

Analyst Recommendations for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit